Status:
COMPLETED
A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
Lead Sponsor:
BIND Therapeutics
Conditions:
KRAS Positive Patients With Non-small Cell Lung Cancer
Squamous Cell Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation positive or squamous cell non-small ...
Eligibility Criteria
Inclusion
- Males or females at least 18 years of age
- Diagnosis of NSCLC with locally advanced or metastatic disease
- Positive for KRAS mutation or Squamous cell histology
- Previously treated with one platinum-based chemotherapy
- Disease status must be that of measurable and/or evaluable disease
- Performance status of 0 to 1 on the ECOG Scale
- Prior chemotherapy completed at least 3 weeks prior to study enrollment
- Prior radiation therapy allowed to \< 25% of the bone marrow
- Patient compliance and geographic proximity that allow adequate follow-up
- Adequate organ function
- Patients with reproductive potential must use contraceptive methods
- Signed informed consent from patient
Exclusion
- Active infection
- Pregnancy or planning to become pregnant
- Breast feeding
- Serious concomitant systemic disorders
- Second primary malignancy
- Patients who are symptomatic from brain metastasis
- Presence of detectable (by physical exam) third-space fluid collections
- More than 1 prior cytotoxic chemotherapy regimen for advanced disease
- Prior treatment with docetaxel
- History of severe hypersensitivity reaction to polysorbate 80
- Peripheral neuropathy at study entry
- Patients known to be HIV positive
- Patients known to be seropositive for hepatitis C hepatitis B
- Congenital long QT syndrome, congestive heart failure, or bradyarrhythmia
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT02283320
Start Date
September 1 2014
End Date
April 1 2016
Last Update
April 18 2016
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site: #51
Chandler, Arizona, United States, 85224
2
Investigative Site: #30
Goodyear, Arizona, United States, 85338
3
Investigative Site: #44
Phoenix, Arizona, United States, 85016
4
Investigative Site: #41
Sedona, Arizona, United States, 86336